Brazil Proposes Injectable HIV PrEP in Public System

What Is Injectable PrEP and How Does It Work?

Injectable PrEP (pre-exposure prophylaxis) uses cabotegravir, a long-acting antiretroviral drug administered as an injection every two months. Unlike the daily oral pill, this option removes the need to remember a tablet every day, potentially improving adherence among people at higher risk of HIV infection.

What Did Brazil's Ministry of Health Propose?

The Brazilian Ministry of Health presented a proposal to include injectable PrEP with cabotegravir in the SUS (Sistema Único de Saúde), Brazil's public health system. The initiative was announced at an international conference and will now be reviewed by Conitec, the National Committee for Health Technology Incorporation, which assesses whether new treatments should be funded publicly.

Why Does This Matter for People in Brazil?

Brazil already offers oral PrEP free of charge through the SUS, making it one of the leading countries in HIV prevention in Latin America. Adding an injectable option could benefit people who struggle with daily pill adherence, including young adults, people experiencing stigma, or those with complex routines. If approved, cabotegravir injections would be available at no cost to eligible patients through public health units.

What Happens Next?

Conitec will analyse the scientific evidence, cost-effectiveness and operational feasibility before making a recommendation to the Ministry of Health. The committee's decisions typically involve public consultation, giving civil society and health professionals a chance to contribute. Only after a positive recommendation and ministerial approval would the drug be incorporated into SUS protocols.